The Outcomes Research Program has the following four specific aims: 1) Evaluate the outcomes of cancer, including health-related quality of life, in a broad range of health care settings 2) Assess the effectiveness and costs of new &established interventions to prevent, detect and treat cancer 3) Identity determinants of the quality of cancer care 4) Characterize barriers to optimal care with a special focus on racial, ethnic and socioeconomic disparities in cancer care and approaches to eliminate disparities in care To achieve these objectives, the Program has assembled a multi-disciplinary group of investigators with demonstrated expertise in the methods of health services research and a proven commitment to the study of cancer outcomes. Their research spans the continuum from basic methodological studies, through clinical applications, to policy applications. The Program was originally funded in 2000 when Dana-Farber/Harvard Cancer Center was established, and it was rated as """"""""outstanding"""""""" in the last renewal in 2005. The Program is led by J. Ayanian(BWH) and J.Weeks(DFCI) and currently has 54 members from 11 HMS departments and three HSPH departments with representation from all seven member institutions. In 2009, Program members were awarded $14.2 million in research funding (total costs), which includes over $9 million in NCI funding and $2.8 million in other federal peer-reviewed funding. The total number of publications from members of the Program during the project period (2006 to 2010) was 1,055. Ofthese 17% ofthese were intra-programmatic collaborations, 33% were inter-programmatic, and 24% were inter-institutional.

Public Health Relevance

The Outcomes Research Program focuses on enhancing the effectiveness and cost-effectiveness of interventions to prevent, diagnose and treat cancer and its consequences. The primary focus is on evaluating interventions that optimize patient-oriented outcomes, identifying barriers to optimal care of all patients, defining approaches to eliminate these barriers, and ensuring that society's resources are allocated effectively to achieve those goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601468
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,471
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications